Glonghui, September 15 | Morgan Stanley Research Report, Fosun Pharmaceuticals (2196.HK)'s earnings forecast per share for 2023 to 2025 was lowered by 6% to 14%, and the target price was lowered from HK$25 to HK$23, taking into account the decline in business contributions related to the COVID-19 pandemic and the slowdown in the launch of new products under anti-corruption actions in the Mainland. The bank pointed out that as a comprehensive healthcare company, Fosun Pharmaceuticals is involved in almost all segments of China's healthcare value chain. Production lines continue to improve, and investment in R&D projects continues to increase, but due to weak profit prospects, reduced COVID-19 related business contributions, and a slowdown in new product growth this year, it currently maintains a cautious view, and the rating is in sync with the big market.